Large animal models gain traction in right heart failure research
Bottom line
Large animal models are getting renewed attention as a missing link in pulmonary hypertension research, according to a new review in the European Respiratory Review. The paper argues that right heart failure is the main driver of morbidity and mortality in pulmonary arterial hypertension, yet there are still no chronic drugs approved specifically to improve right heart function in people. The authors say one reason may be overreliance on rodent data, while large animal models can better mirror human heart size, anatomy, hemodynamics, imaging, and device testing needs. Prior reviews and experimental papers cited in the field have similarly described large animal models as a key translational step, especially for studying right ventricular remodeling and failure under clinically relevant conditions. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this is a reminder that food animal and other large animal species are increasingly central to translational cardiopulmonary research, not just as stand-ins for rodent findings, but as platforms for more clinically realistic physiology, imaging, catheterization, and interventional studies. That has implications for research partnerships, animal welfare oversight, protocol design, and the demand for veterinarians with expertise in large animal anesthesia, perioperative care, cardiology, and humane endpoint monitoring. Reviews in the space note that model selection is critical because no single system fully reproduces human pulmonary hypertension, and the strengths of large animal models must be weighed against cost, complexity, and ethics. (pmc.ncbi.nlm.nih.gov)
What to watch: Expect more work aimed at standardizing which large animal models are best suited for drug testing, exercise studies, and device development in right heart failure linked to pulmonary hypertension. (pubmed.ncbi.nlm.nih.gov)
Key facts
- Topic
- Large animal models of right heart failure in pulmonary hypertension
- Journal
- European Respiratory Review
- Main clinical problem
- Right heart failure drives morbidity and mortality in pulmonary arterial hypertension
- Current treatment gap
- There are no chronic drugs approved specifically to improve right heart function in people
- Why large animals matter
- They better mirror human heart size, anatomy, hemodynamics, imaging, and device testing needs
- Limitation of current approach
- The field may be overrelying on rodent data
- Research direction
- More work is expected on standardizing which large animal models fit drug testing, exercise studies, and device development
A new review in the European Respiratory Review makes a straightforward case: if pulmonary hypertension therapies are going to translate more reliably into human benefit, researchers may need to spend more time in large animal models of right heart failure. The authors frame right heart failure as the main driver of poor outcomes in pulmonary arterial hypertension and argue that the field still lacks chronic pharmaceutical options that directly support right heart function in human patients, despite encouraging preclinical signals from rodent work. (pmc.ncbi.nlm.nih.gov)
That translational gap isn’t a new concern, but it’s becoming harder to ignore. Earlier reviews of right ventricular failure and pulmonary hypertension models have repeatedly noted that animal studies often fail to predict clinical performance, in part because many models capture only pieces of the disease. Large animal work has been positioned for years as a bridge between basic discovery and clinical application because it allows more human-like anatomy, surgical access, hemodynamic monitoring, imaging, and device evaluation than most rodent systems can offer. (pubmed.ncbi.nlm.nih.gov)
The broader literature shows why interest is growing now. Investigators have developed sheep, pig, and other large animal models that can reproduce chronic pulmonary hypertension, right ventricular hypertrophy, maladaptive remodeling, and, in some cases, overt right heart failure. Examples include ovine models using pulmonary artery ligation and banding, chronic embolization approaches, and other pressure-overload systems designed to mimic different disease pathways. Researchers have also continued refining these models for more specific use cases, including exercise physiology and functional phenotyping. (pmc.ncbi.nlm.nih.gov)
Industry-style reaction wasn’t readily available in the public search results, but the expert tone across recent reviews is consistent: model choice matters, and no single model can answer every translational question. A 2020 review of animal models of right heart failure emphasized that therapies directly targeting the failing right heart remain absent and that selecting the right model is essential for meaningful translation. Other reviews have echoed that caution, especially in pulmonary hypertension, where vascular remodeling, right ventricular adaptation, and progression to failure can differ substantially across experimental systems. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, especially those involved in academic medicine, contract research, and comparative cardiology, this review reinforces the strategic importance of large animal expertise. These studies depend on veterinary teams for anesthesia, longitudinal welfare monitoring, imaging support, catheter-based procedures, pathology, and endpoint assessment. They also raise familiar questions around ethics, cost, reproducibility, and whether a given model truly matches the biology a sponsor wants to study. In practical terms, veterinarians are part of the translational filter: they help determine whether a model is robust enough, humane enough, and clinically relevant enough to justify moving a therapy or device closer to human trials. (pubmed.ncbi.nlm.nih.gov)
There’s also a profession-wide relevance beyond the lab. As cardiopulmonary device development and precision phenotyping expand, large animal studies may create more demand for veterinarians who can work across species, interpret advanced cardiovascular endpoints, and collaborate with physician-scientists and engineers. That’s particularly true in right heart failure, where the field is still trying to define which preclinical signals best predict success in people. (pmc.ncbi.nlm.nih.gov)
What to watch: The next phase is likely to focus less on whether large animal models are useful, and more on which models are most predictive for specific drug, biologic, exercise, and device questions, with increasing pressure to standardize phenotyping and improve cross-study comparability. (pmc.ncbi.nlm.nih.gov)